Q BioMed Inc has a winner in cancer bone pain drug Strontium89 and a deep pipeline of biomedical assets proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Q BioMed Insider to Invest up to $30M in the Company
Aedesius Holdings Ltd. (AedesiusOne), a privately held global disruption aggregator, enters Into $30M Securities Purchase Agreement with Q BioMed
Up front investment of up to $20M with an optional $10M in 6 month warrants
Proceeds may be used for deploying contract sales force, advancing pipeline, redeeming outstanding convertible debt and convertible preferred shares and acquiring later-stage asset(s)
News provided by
Share this article
QBIO), announced today that it has signed a securities purchase agreement ( Transaction ) with Aedesius Holdings Ltd (AedesiusOne), a privately owned United Kingdom based healthcare and technology aggregator. AedesiusOne is run by Geoffrey Fatzinger, our Global Head of Regulatory Affairs. The agreement gives AedesiusOne the opportunity to buy approximately 43% of the outstanding QBIO shares for an aggregate of $30,000,000. The Transaction is structured as an initial investment of $5,000,000
NA Proactive news snapshot: Tartisan Nickel, Metalla Royalty & Streaming, Dalrada Corporation, Numinus Wellness UPDATE. …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Tartisan Nickel Corp (CSE:TN) (OTCMKTS:TTSRF) (FRA:8TA) released a National Instrument (NI) 43-101 Technical Report, prepared by SMX International Corporation, on the Sill Lake Lead-Silver property, consisting of 47 unpatented mining claims in Van Koughnet Township, about 30 kilometres north of Sault Saint Marie, Ontario. The NI 43-101 Report is essentially the validation and reinterpretation of the work previously done by Chemrox Technologies LLC, documentation of the current claims package held by Tartisan, plus an examination of an airborne spectrographic report prepared by Steele and Associates. SMX validated the model and resource numbers generated by Chemrox Technologies, which estimated an Inferred s
Q BioMed Inc thrilled with $30M insider investment to help advance its pipeline of therapeutics
Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the privately held global disruption aggregator Aedesius Holdings Ltd, run by Geoffrey Fatzinger, Q BioMed s global head of regulatory affairs, has committed to investing up to $30 million in the company via a securities agreement. Corin says its the largest single investment so far for the biotech, allowing the group to move forward with its commercial roll-out plans for its cancer bone pain drug Strontium89, as well as advance its development opportunities.
Quick facts: Q BioMed Inc.
Q BioMed announces up to $30M investment from insider, allowing it to advance company s growth plans
The company has inked a securities purchase agreement with AedesiusOne, which is run by Geoffrey Fatzinger, Q BioMed s global head of regulatory affairs Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector
Q BioMed Inc (OTCQB:QBIO) has unveiled its largest single investment so far, with Aedesius Holdings Ltd (AedesiusOne), a privately held global disruption aggregator, investing up to $30 million in the company via a securities agreement.
The biotech accelerator noted that AedesiusOne is run by Geoffrey Fatzinger, Q BioMed s global head of regulatory affairs.